Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物自愿披露关于9MW2821在2026年美国临床肿瘤学会（ASCO）以口头报告和壁报形式报告最新临床数据的公告
Regulatory Filings Classification · 67% confidence The document is a voluntary corporate announcement disclosing clinical trial data to be presented at the 2026 ASCO conference. It contains no financial statements or management discussion of financial performance, nor is it a shareholder meeting notice, earnings release, or regulatory certification. It is a general regulatory disclosure of clinical data, which falls under the fallback category “Regulatory Filings (RNS).”
2026-05-21 Chinese
迈威生物2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "迈威（上海）生物科技股份有限公司2026年第一季度报告" which translates to "Maiwei (Shanghai) Biotechnology Co., Ltd. 2026 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, and management commentary for the first quarter of 2026. The report explicitly states it is a quarterly report and includes unaudited financial statements for the quarter ending March 31, 2026. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-28 Chinese
迈威生物关于境外上市外资股（H股）公开发行价格的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pricing and listing details of the company's overseas H-share public offering on the Hong Kong Stock Exchange. It includes the final issue price, listing date, and legal disclaimers. The content is focused on capital raising and listing activities rather than a full financial report or earnings release. The document length is short (691 characters), and it is clearly an announcement of a capital market transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-04-24 Chinese
迈威生物关于2025年年度股东会增加会议地址的公告
AGM Information Classification · 95% confidence The document is an announcement regarding the addition of a meeting location for the 2025 Annual General Meeting (AGM) of the company. It includes details about the meeting date, locations, voting system, and agenda items to be discussed at the AGM. It does not contain the actual AGM materials or presentations but rather logistical information about the meeting itself. The document length is under 5,000 characters and serves as a notice about the AGM arrangements rather than the AGM content or report. Therefore, it fits the category of AGM Information (AGM-R).
2026-04-23 Chinese
迈威生物关于刊发H股招股说明书、H股发行价格区间及H股香港公开发售等事宜的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issuance of H shares, including the publication of the H share prospectus, the price range for the H share issuance, and details about the Hong Kong public offering. It references regulatory approvals and filings with the Hong Kong Stock Exchange and the China Securities Regulatory Commission. The document does not contain financial statements or detailed financial analysis but rather provides information about the capital raising and share issuance process. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and focused on the issuance details, not a full report or prospectus itself, but an announcement about the issuance and related documents.
2026-04-19 Chinese
迈威生物自愿披露关于迈卫健?注射液增加适应症补充申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the acceptance of a supplementary application for a new drug indication by the National Medical Products Administration. It details the drug, its clinical trial results, regulatory approvals, and market information. The document is relatively short (2248 characters) and primarily serves as a formal notification of regulatory acceptance and risk disclosure to investors. It does not contain financial statements, detailed financial analysis, or management discussion of financial results. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a proxy, voting result, or management change announcement. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about drug approval progress and related risk disclosures, which do not fit other specific categories.
2026-04-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.